Arctic Bioscience – CFO change


Arctic Bioscience, a biotech company developing and commercializing pharmaceutical and nutraceutical products based on the unique properties of bioactive marine compounds, announces that CFO Danielle Glenn has terminated her consulting agreement and accepted a position with another company. Glenn has been with the company since September 2020. The search for a new permanent CFO has been initiated.

“Arctic Bioscience has taken major steps over the past years, with several initiatives in both pharma and nutraceuticals and the development of a new production facility at the North- West coast of Norway. In addition, the company has listed on the Euronext Growth platform, supporting the company’s growth strategy. I would like to thank Danielle for her contributions to this development”, says Harald Nordal, Chairman of the Board in Arctic Bioscience.

“Arctic Bioscience will continue to capture its commercial and strategic opportunities, develop new alliances and execute on the upcoming phase II study for our psoriasis drug candidate. Our incoming CEO Christer Valderhaug will align his management team, including the new CFO with this exciting growth strategy “, says Nordal

Danielle Glenn will continue as CFO through April 2022.

For more information, please contact

Harald Nordal, COB Arctic Bioscience

Phone: +47 908 59 397

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing nutraceutical products based on herring roe oil. Herring roe oil contains lipids that are essential to maintain cell membranes, contributing to normal functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients to other companies making dietary supplements, and as finished goods under the Romega brand. The strategy is to switch sales from bulk to finished goods and focus markets are USA and China.

The company is developing HRO350 – a novel investigational drug candidate with herring roe as raw material. HRO350 is being developed for treatment of mild-to -moderate psoriasis. This is a large patient group in need of new effective medicines. Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Documents & Links

220131_ABS_SER_CFO resigns_FINAL